GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » ROA %

Firebrick Pharma (ASX:FRE) ROA % : -136.38% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Firebrick Pharma's annualized Net Income for the quarter that ended in Dec. 2024 was A$-2.89 Mil. Firebrick Pharma's average Total Assets over the quarter that ended in Dec. 2024 was A$2.12 Mil. Therefore, Firebrick Pharma's annualized ROA % for the quarter that ended in Dec. 2024 was -136.38%.

The historical rank and industry rank for Firebrick Pharma's ROA % or its related term are showing as below:

ASX:FRE' s ROA % Range Over the Past 10 Years
Min: -116.16   Med: -43.65   Max: -37.04
Current: -83.56

During the past 4 years, Firebrick Pharma's highest ROA % was -37.04%. The lowest was -116.16%. And the median was -43.65%.

ASX:FRE's ROA % is ranked worse than
93.62% of 1034 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs ASX:FRE: -83.56

Firebrick Pharma ROA % Historical Data

The historical data trend for Firebrick Pharma's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma ROA % Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
ROA %
- -37.04 -116.16 -43.65

Firebrick Pharma Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROA % Get a 7-Day Free Trial -87.28 -170.56 -72.90 -25.47 -136.38

Competitive Comparison of Firebrick Pharma's ROA %

For the Drug Manufacturers - General subindustry, Firebrick Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Firebrick Pharma's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's ROA % distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's ROA % falls into.



Firebrick Pharma ROA % Calculation

Firebrick Pharma's annualized ROA % for the fiscal year that ended in Jun. 2024 is calculated as:

ROA %=Net Income (A: Jun. 2024 )/( (Total Assets (A: Jun. 2023 )+Total Assets (A: Jun. 2024 ))/ count )
=-1.176/( (2.982+2.406)/ 2 )
=-1.176/2.694
=-43.65 %

Firebrick Pharma's annualized ROA % for the quarter that ended in Dec. 2024 is calculated as:

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-2.892/( (2.406+1.835)/ 2 )
=-2.892/2.1205
=-136.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2024) net income data. ROA % is displayed in the 30-year financial page.


Firebrick Pharma  (ASX:FRE) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-2.892/2.1205
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-2.892 / 0)*(0 / 2.1205)
=Net Margin %*Asset Turnover
=N/A %*0
=-136.38 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2024) net income data. The Revenue data used here is two times the semi-annual (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Firebrick Pharma ROA % Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Firebrick Pharma Business Description

Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines